BHAGIRADHA CHEMICALS & INDUSTRIES LTD. Q1 FY27 Results

Bhagiradha Chemicals & Industries reported consolidated revenue of ₹195.02 Cr for Q1 FY27, up 57.6% YoY (₹123.78 Cr) and 23.3% QoQ (₹158.10 Cr), with consolidated PAT of ₹13.33 Cr — up ~235% YoY (₹3.98 Cr) and ~227% QoQ (₹4.07 Cr). Consolidated EPS was ₹1.03 versus ₹0.31 in both the year-ago and preceding quarters. There were no exceptional items in either period, so this is a genuine operating print rather than a one-off-driven number.

The scale of the YoY jump is not organic to the parent alone: standalone PAT was ₹10.68 Cr, up a comparatively modest 28.9% YoY (₹8.29 Cr), and standalone revenue of ₹173.67 Cr grew 40.3% YoY versus the parent's own base. The gap between standalone (+28.9%) and consolidated (+235%) PAT growth is driven entirely by wholly-owned subsidiary Bheema Fine Chemicals, which swung from an implied ₹4.31 Cr loss in Q1 FY26 (consolidated PAT of ₹3.98 Cr sat below standalone PAT of ₹8.29 Cr that quarter) to an implied ₹2.65 Cr profit this quarter. That subsidiary turnaround, rather than any change at the parent, is the reason the consolidated headline dramatically outpaces the standalone one — both figures are genuine, but readers seeing only the standalone number would see a much smaller improvement.

The stock went into the print at ₹314.8, up 11.6% over the past month of trading.

For context: this is the highest quarterly PAT in the last 6 quarters on our records; revenue is at a 6-quarter high.

Margins expanded across the board: consolidated operating margin rose to 15.65% from 7.26% YoY and 12.28% QoQ, while net margin improved to 6.84% from 3.21% YoY and 2.58% QoQ, consistent with the subsidiary's swing to profitability lifting group-level cost absorption. No street/consensus estimates could be verified for this stock — a web search returned figures for the similarly named but unrelated Bhageria Industries, which is not this company, so vsStreet is marked unknown rather than relying on that mismatch. The company and our records carry no formal management guidance or prior concall commentary, and no press release beyond the regulatory filing was available, so there is no outlook to grade the print against; the filing itself only carries board-meeting administrative notes (AGM, BRSR filing, trading-window closure) with no direct bearing on this quarter's numbers. Both the standalone and consolidated statements carry an unmodified limited-review opinion from the statutory auditors.